Background: Defensins are antimicrobial peptides that exert immunomodulatory and chemotactic functions. Based on these properties and their high expression levels in the skin, they are likely to affect skin inflammation, infection, and wound healing. This may lead to therapeutic applications in (burn) wound healing. Objective: We aimed to investigate the effects of human β-defensins (hBDs) on keratinocytes and fibroblasts, 2 major skin cell types involved in skin regeneration. Methods: Monolayer keratinocyte and fibroblast cultures were exposed to recombinant hBDs, and we overexpressed hBD2 and hBD3 in keratinocytes of reconstructed epidermal equivalents by lentiviral transduction. The effects were measured by immunohistochemistry, quantitative real-time PCR, and migration assays. Kinome analyses were performed on cultured keratinocytes to investigate the signal transduction events elicited by hBD stimulation. Results: We found that hBD3 induced the expression of cytokines and chemokines in keratinocytes, which was not observed in fibroblasts. hBD2, however, stimulated cell migration only in fibroblasts, which was not found for hBD3. Both defensins are likely to exert receptor-mediated effects in keratinocytes, as witnessed by changes in protein kinase activation following stimulation by hBD2 and hBD3. Kinome analysis suggested that protein kinase C activation was a common event for both defensins. We observed, however, considerable differences in keratinocyte responses between stimulation by exogenous recombinant defensins and endogenous defensins expressed following lentiviral transduction. Conclusion: Defensins exert modest biological effects on skin cells that are potentially beneficial in wound healing, but many questions regarding the biological mechanisms of action and relevance for the in vivo situation are still remaining.

Keywords:
Keratinocytes, Fibroblasts, β-Defensins, Wound healing
1.
Medzhitov R, Janeway CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91:295-298.
2.
Schroder JM, Harder J: Antimicrobial skin peptides and proteins. Cell Mol Life Sci 2006;63:469-486.
3.
Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710-720.
4.
Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, Ganz T: Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol 2002;118:275-281.
5.
Harder J, Schroder JM: Antimicrobial peptides in human skin. Chem Immunol Allergy 2005;86:22-41.
6.
Semple F, Dorin JR: Beta-defensins: multifunctional modulators of infection, inflammation and more? J Innate Immun 2012;4:337-348.
7.
Yang D, Chen Q, Chertov O, Oppenheim JJ: Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000;68:9-14.
8.
Yang D, Biragyn A, Kwak LW, Oppenheim JJ: Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002;23:291-296.
9.
Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-528.
10.
Nagaoka I, Niyonsaba F, Tsutsumi-Ishii Y, Tamura H, Hirata M: Evaluation of the effect of human beta-defensins on neutrophil apoptosis. Int Immunol 2008;20:543-553.
11.
Soruri A, Grigat J, Forssmann U, Riggert J, Zwirner J: Beta-defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol 2007;37:2474-2486.
12.
Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, Van de Kerkhof PC, Traupe H, de Jongh GJ, den Heijer M, Reis A, Armour JA, Schalkwijk J: Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-25.
13.
Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ, van Vlijmen-Willems IM, Bergboer JG, van Rossum MM, de Jong EM, den Heijjer M, Evers AW, Bergers M, Armour JA, Zeeuwen PL, Schalkwijk J: Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009;4:e4725.
14.
Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, Nagaoka I, Okumura K, Ogawa H: Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007;127:594-604.
15.
Frye M, Bargon J, Gropp R: Expression of human beta-defensin-1 promotes differentiation of keratinocytes. J Mol Med 2001;79:275-282.
16.
Hirsch T, Spielmann M, Zuhaili B, Fossum M, Metzig M, Koehler T, Steinau HU, Yao F, Onderdonk AB, Steinstraesser L, Eriksson E: Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Gene Med 2009;11:220-228.
17.
Kiatsurayanon C, Niyonsaba F, Smithrithee R, Akiyama T, Ushio H, Hara M, Okumura K, Ikeda S, Ogawa H: Host defense (antimicrobial) peptide, human beta-defensin-3, improves the function of the epithelial tight-junction barrier in human keratinocytes. J Invest Dermatol 2014;134:2163-2173.
18.
Gibson AL, Thomas-Virnig CL, Centanni JM, Schlosser SJ, Johnston CE, Van Winkle KF, Szilagyi A, He LK, Shankar R, Allen-Hoffmann BL: Nonviral human beta defensin-3 expression in a bioengineered human skin tissue: a therapeutic alternative for infected wounds. Wound Repair Regen 2012;20:414-424.
19.
Wang B, McHugh BJ, Qureshi A, Campopiano DJ, Clarke DJ, Fitzgerald JR, Dorin JR, Weller R, Davidson DJ: IL-1beta-induced protection of keratinocytes against Staphylococcus aureus-secreted proteases is mediated by human beta-defensin 2. J Invest Dermatol 2017;137:95-105.
20.
Tjabringa G, Bergers M, van Rens D, de Boer R, Lamme E, Schalkwijk J: Development and validation of human psoriatic skin equivalents. Am J Pathol 2008;173:815-823.
21.
Van den Bogaard E, Rodijk-Olthuis D, Jansen PA, van Vlijmen-Willems IM, van Erp PE, Joosten I, Zeeuwen PL, Schalkwijk J: Rho kinase inhibitor Y-27632 prolongs the life span of adult human keratinocytes, enhances skin equivalent development and facilitates lentiviral transduction. Tissue Eng Part A 2012;18:1827-1836.
22.
De Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, Dogan A, Hiemstra PS, Van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005;125:1163-1173.
23.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
24.
Kamsteeg M, Bergers M, de Boer R, Zeeuwen PL, Hato SV, Schalkwijk J, Tjabringa GS: Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent. Am J Pathol 2011;178:2091-2099.
25.
Jansen PA, van den Bogaard EH, Kersten FF, Oostendorp C, van Vlijmen-Willems IM, Oji V, Traupe H, Hennies HC, Schalkwijk J, Zeeuwen PL: Cystatin M/E knockdown by lentiviral delivery of shRNA impairs epidermal morphogenesis of human skin equivalents. Exp Dermatol 2012;21:889-891.
26.
Van den Bogaard EH, Tjabringa GS, Joosten I, Vonk-Bergers M, van Rijssen E, Tijssen HJ, Erkens M, Schalkwijk J, Koenen HJ: Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. J Invest Dermatol 2014;134:719-727.
27.
Niehues H, van Vlijmen-Willems IM, Bergboer JG, Kersten FF, Narita M, Hendriks WJ, van den Bogaard EH, Zeeuwen PL, Schalkwijk J: Late cornified envelope (LCE) proteins: distinct expression patterns of LCE2 and LCE3 members suggest non-redundant roles in human epidermis and other epithelia. Br J Dermatol 2016;174:795-802.
28.
Smithrithee R, Niyonsaba F, Kiatsurayanon C, Ushio H, Ikeda S, Okumura K, Ogawa H: Human beta-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes. J Dermatol Sci 2015;77:46-53.
29.
Gomes AP, Mano JF, Queiroz JA, Gouveia IC: Incorporation of antimicrobial peptides on functionalized cotton gauzes for medical applications. Carbohydr Polym 2015;127:451-461.
30.
Kanda N, Kamata M, Tada Y, Ishikawa T, Sato S, Watanabe S: Human beta-defensin-2 enhances IFN-gamma and IL-10 production and suppresses IL-17 production in T cells. J Leukoc Biol 2011;89:935-944.
31.
Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW: Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298:1025-1029.
32.
Semple F, Webb S, Li HN, Patel HB, Perretti M, Jackson IJ, Gray M, Davidson DJ, Dorin JR: Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 2010;40:1073-1078.
33.
Lai Y, Cogen AL, Radek KA, Park HJ, Macleod DT, Leichtle A, Ryan AF, Di Nardo A, Gallo RL: Activation of TLR2 by a small molecule produced by Staphylococcus epidermidis increases antimicrobial defense against bacterial skin infections. J Invest Dermatol 2010;130:2211-2221.
34.
Cristofaro P, Opal SM: Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 2006;66:15-29.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.